Ian W. Flinn, MD, PhD
With several approvals this past year, chimeric antigen receptor (CAR) T-cell therapy is becoming a significant part of treatment for select patients with hematologic malignancies.
State of the Science Summit™, A Summer of Progress: Updates from ASCO 2018, Flinn, director of lymphoma research, principal investigator, Sarah Cannon Research Institute, discussed the latest developments with CAR T-cell therapies and other recent advances in the field of lymphoma.
OncLive: Can you provide some background to your presentation on lymphoma?
I spoke about a number of different presentations that have occurred over the last 6 months, at the 2018 ASCO Annual Meeting and other meetings, looking at advances in both Hodgkin lymphoma and NHL, including small molecule inhibitors, chemotherapy, and CAR T-cell therapy.
What are some key updates from these recent data?
In follicular lymphoma, one of the key updates is the RELEVANCE study that compared rituximab (Rituxan) and chemotherapy with rituximab and lenalidomide (Revlimid; R2
). This study was a large, international trial. It was based on some phase II data that suggested the R2
regimen, rituximab plus lenalidomide, had very high remission rates and very tolerable toxicity. Therefore, that was an exciting phase II study that led to this randomized trial.
... to read the full story